INTRODUCTION

Left ventricular (LV) wall thickening, or LV hypertrophy (LVH), is common and occurs in diverse conditions including hypertrophic cardiomyopathy (HCM), hypertensive heart disease, aortic valve stenosis, lysosomal storage disorders, cardiac amyloidosis, mitochondrial cardiomyopathy, sarcoidosis and athlete's heart. Cardiac magnetic resonance (CMR) imaging provides various tissue contrasts and characteristics that reflect histological changes in the myocardium, such as cellular hypertrophy, cardiomyocyte disarray, interstitial fibrosis, extracellular accumulation of insoluble proteins, intracellular accumulation of fat, and intracellular vacuolar changes. Therefore, CMR imaging may be beneficial in establishing a differential diagnosis of LVH. Although various diseases share LV wall thickening as a common feature, the histologic changes that underscore each disease are distinct. This review focuses on CMR multiparametric myocardial analysis, which may provide clues for the differentiation of thickened myocardium based on the histologic features of HCM and its phenocopies.

Keywords: Hypertrophy, left ventricular; Heart; Magnetic resonance imaging; Pathology; Histology; Diagnosis, differential
of the heart constitute CMR features, including LV wall thickness, native T1 values, T2 values, and extracellular volume (ECV) fractions (Fig. 1). Various diseases characterized by LVH exhibit distinct histological features, such as cellular hypertrophy, cardiomyocyte disarray, interstitial fibrosis, extracellular accumulation of insoluble proteins, intracellular accumulation of fat, and intracellular vacuolar changes. These characteristics result in differential features in CMR multiparametric myocardial analysis and characterization of myocardial tissue, which may facilitate differential diagnosis. The aim of this article was to discuss relevant CMR features for the differentiation of thickened myocardium, with an emphasis on the intrinsic histologic features of HCM and its phenocopies.

Hypertrophic Cardiomyopathy

HCM comprises a heterogeneous group of diseases
associated with sarcomere gene mutations, which are typically transmitted in an autosomal dominant pattern [3]. The natural disease course is diverse, ranging from no symptoms in mutation carriers to dyspnea, chest pain, syncope, and sudden cardiac death (SCD) [10,11]. Indeed, HCM is the most common cause of SCD in young individuals and athletes [12]. Thus, the accurate diagnosis of HCM is clinically significant. The diagnosis of HCM is generally based on imaging features. The asymmetric septal type is the most common morphological type of HCM [13]. The widely accepted diagnostic criteria for this type of HCM are LV end-diastolic wall thickness (EDWT) ≥ 15 mm or septal-to-lateral wall thickness ratio > 1.3 in the absence of LV chamber dilatation and other systemic diseases [14,15]. In apical HCM, myocardial thickening is confined to the LV apex and measures ≥ 15 mm, with an apical-to-basal LV wall thickness ratio of 1.3–1.5 [16,17]. Nevertheless, differentiation of HCM from its phenocopies based on imaging features. The asymmetric septal type is the most common morphological type of HCM [13]. The widely accepted diagnostic criteria for this type of HCM are LV end-diastolic wall thickness (EDWT) ≥ 15 mm or septal-to-lateral wall thickness ratio > 1.3 in the absence of LV chamber dilatation and other systemic diseases [14,15]. In apical HCM, myocardial thickening is confined to the LV apex and measures ≥ 15 mm, with an apical-to-basal LV wall thickness ratio of 1.3–1.5 [16,17]. Nevertheless, differentiation of HCM from its phenocopies based on myocardial thickness alone can be unreliable [18].

Histologically, the thickened myocardium in HCM exhibits structural abnormalities, including myofibrillar disarray, myocardial injury, replacement fibrosis, and an increase in interstitial connective tissue [16]. CMR imaging may facilitate the accurate diagnosis of HCM because of its ability to provide still images at end-diastole for precise measurement of myocardial thickness and because of its unique tissue characterization capabilities [19]. Conventionally, myocardial replacement fibrosis and scarring are identified using late gadolinium enhancement (LGE) imaging. Gadolinium contrast agents accumulate within the extracellular space in areas with scarring and are commonly described as patchy enhancements in the thickened myocardium [20–22]. However, almost half of patients with HCM have been reported to lack LGE on CMR imaging [23,24]. In such cases, multiparametric mapping techniques support the evaluation of distinct myocardial conditions. Patients with HCM exhibit increased native T1 and ECV fractions, reflecting the accumulation of interstitial fibrosis within an enlarged extracellular matrix. Prolonged T1 and elevated ECV fractions have been observed even in the absence of regional LGE and hemodynamic obstruction in HCM [25]. Patients with HCM may also exhibit an elevated native T2 value, which is associated with myocardial edema, inflammation, and increased risk of SCD [26,27]. In addition, strain imaging has provided evidence of myocardial disarray with decreased global longitudinal strain (GLS) parameters despite preservation of LV systolic function (Fig. 2) [28].

**Hypertensive Heart Disease**

HHD arises due to systemic hypertension, and increased blood pressure accentuates hypertrophic remodeling via an increase in afterload and LV wall stress [29]. HHD typically manifests as concentric hypertrophy, absence of cardiac chamber dilatation, and LV wall thickness < 15 mm [30]. However, distinguishing HHD from HCM can be challenging if LV EDWT exceeds 15 mm [31] because HHD occurs as a result of pathological remodeling, similar to HCM [32]. One study reported that the segmental distribution of EDWT was not significantly different between the two groups [29]. LGE is more common in patients with HCM; however, half of the patients with HHD may exhibit LGE on CMR images. Although HCM more frequently presents as LGE at the right ventricular (RV) insertion point, LGE is less reliable for differentiating HHD from HCM [29,33,34]. Compared to those in normal controls, native T1 values and the ECV fraction are also increased in patients with HHD and LVH; therefore, these parameters are less useful for differentiating HHD from HCM (Fig. 3) [35].

Examination of histological changes may be useful for differential diagnosis. Histologically, HHD manifests as parallel alignment of hypertrophic cardiomyocytes [36]. In contrast, HCM presents with a disorganized arrangement of hypertrophic cardiomyocytes. Kato et al. [36] evaluated strain rates using tissue Doppler ultrasonography and reported that the septum/posterior wall thickness ratio was significantly higher in patients with HCM than in those with HHD, whereas the mean values of systolic strain were significantly higher in patients with HHD than in those with HCM. Notably, using these two parameters, that is, septum/posterior wall thickness ratio and systolic strain, HHD could be distinguished from HCM with 91% accuracy. Similarly, CMR imaging has been successfully applied for the differential diagnosis of HCM and HHD [29]. Puntmann et al. [34] reported that LV strain measured using cine images revealed that HCM was characterized by reduced global and regional deformation with preserved LV systolic function. In contrast, concentric LVH and relatively spared LV strain were suggestive of HHD rather than HCM. However, Neisius et al. [28] reported that there were no significant differences in strain parameters between HHD and HCM subgroups with equal LV wall thickness, although GLS was higher in patients with HHD. Accordingly, careful investigations that
consider the clinical scenario, multiparametric MR data, follow-up, and treatment responses are warranted to ensure an accurate diagnosis of HHD [18].

Aortic Valve Stenosis

AS is the most common valvular heart disease and can progress to afterload-induced heart failure [37,38]. LV responses and adaptations to AS are heterogeneous, ranging from normal geometry to concentric, asymmetrical, and eccentric remodeling and hypertrophy [39]. LVH is a well-known sequela of chronic pressure overload due to AS, which is a compensatory mechanism for normalizing wall stress and maintaining cardiac output [40]. Asymmetrical LVH is fairly common and is observed in 27% of patients with AS [41]. Dweck et al. [39] reported that asymmetric

Fig. 2. CMR findings of HCM based on histologic features.

A. A schematic illustration of representative histological findings of HCM includes cardiomyocyte hypertrophy with a disorganized arrangement of fibers and interstitial fibrosis. Variations in muscle fiber thickness and enlarged and hyperchromatic nuclei are characteristic features. B. On short-axis cine images of the end-diastolic phase, the LV wall is thickened, measuring 18 mm. C. LGE imaging reveals patchy hyperenhancement in a thickened myocardium, which correlates histologically with regions of fibrosis. D. The native T1 map shows heterogeneous native T1 values of the myocardium, measuring up to 1320 ms on 3T MRI. E. After contrast media injection, the myocardium showed patchy areas with decreased post-T1 values. F. The T2 map shows increased T2 values of thickened myocardium, measuring up to 45 ms on 3T MRI. G, H. The ECV fraction map (G) and bull’s eye diagram (H) demonstrate increased ECV of the myocardium, up to 50.6%. I. A bull’s eye polar map of the GLS measured on cine images shows decreased absolute strain values in each myocardial segment. CMR = cardiac magnetic resonance, ECV = extracellular volume, GLS = global longitudinal strain, HCM = hypertrophic cardiomyopathy, LGE = late gadolinium enhancement, LV = left ventricular
LVH was most frequently observed in the basal-to-mid septum, with a mean thickness of 17 mm. Thus, HCM and AS may overlap considerably in morphological assessments.

Cardiac cine images may provide clues for the differential diagnosis of AS and HCM. Cine images show the systolic jet of turbulent flow across the aortic valve (AV), with a decreased AV area in AS. In contrast, in patients with HCM, the jet is observed in the subaortic region, resulting from thickening of the adjacent basal LV anteroseptal wall [16].

LGE is less useful for differential diagnosis, as focal delayed hyperenhancement is a frequent finding on LGE imaging in patients with AS (Fig. 4) [42].

Characteristic histological features of AS include cardiomyocyte hypertrophy and extracellular matrix.
expansion with interstitial fibrosis, which eventually leads to cellular apoptosis and subsequent replacement fibrosis [43]. Studies have reported increased native T1 values and ECV fractions in patients with AS, but there may be a substantial overlap with normal control values [40,44]. However, a significant correlation between native T1 values and ECV fractions with AS severity, LV mass, and cardiac function in patients with AS has been reported [44]. In addition, recent studies have demonstrated that ECV is a significant predictor of severe myocardial fibrosis and long-term clinical outcomes in patients with AS, highlighting the prognostic power of CMR markers [45-47]. Furthermore, CMR imaging provides additional insights into LV reverse remodeling after AV replacement. Studies have demonstrated that LV mass regression after surgery results from decreased interstitial fibrosis and regression of

Fig. 4. CMR findings of aortic stenosis based on histologic features.

A. A schematic illustration of representative histological findings in aortic stenosis shows that cardiomyocytes are thickened and nuclei are enlarged with preserved muscle fiber alignment. B. Three-chamber cine image of the systolic phase shows thickened aortic valves with artifacts in the supra-valvular area. C. The left ventricular myocardium is concentrically thickened, measuring up to 18 mm on a short-axis cine image of the end-diastolic phase. D. LGE image reveals multifocal patchy myocardial scarring. E. The native T1 map shows increased native T1 values, measuring up to 1315 ms on 3T MRI. F. On the post-contrast T1 map, the myocardium shows heterogeneous post-T1 values with multifocal patchy foci and decreased T1 values. G. The T2 map shows relatively even myocardial T2 values. H, I. The ECV fraction map (H) and bull’s eye diagram (I) demonstrate an increased ECV fraction in the myocardium. CMR = cardiac magnetic resonance, ECV = extracellular volume, LGE = late gadolinium enhancement.
cardiomyocyte hypertrophy, but focal replacement scarring and LGE do not resolve [45]. In terms of CMR strain analysis in patients with AS, research on the differentiation of AS from various HCM phenotypes using the CMR strain is limited. Instead, various CMR strain studies have focused on predicting myocardial remodeling in patients with AS. Hwang et al. [48] reported that LV GLS is associated with postoperative LV remodeling in patients with severe AS. Peak LV circumferential stains are also reportedly associated with postoperative mortality [49]. In addition, two-dimensional global longitudinal peak strain on CMR has been suggested as a prognostic predictor of clinical cardiac events in asymptomatic patients with AS and preserved cardiac function [50].

**Liposomal Storage Disease**

Anderson-Fabry disease (henceforth referred to as Fabry disease) is a rare genetic multisystem lysosomal storage disorder characterized by intracellular accumulation of glycosphingolipids caused by alpha-galactosidase A deficiency [51]. Cardiac involvement is important for prognosis and is reported in 40%–60% of patients with Fabry disease [52,53]. In cases of Fabry disease with cardiac involvement, ventricular (mainly LV) hypertrophy occurs, resulting in heart failure, valvular abnormality, ischemia, and arrhythmia [53]. Thus, CMR imaging may be a useful tool for the diagnosis of Fabry disease. On cine imaging, concentric LVH is common and the LV mass is increased. Diastolic dysfunction appears first and may be followed by a decrease in systolic function as myocardial fibrosis progresses [53,54]. For CMR strain analysis, Mathur et al. [55] demonstrated that the global longitudinal and circumferential strains from patients with Fabry disease did not differ significantly from those of healthy controls. Instead, they suggested that loss of the base-to-apex circumferential strain gradient might be an early marker of cardiac Fabry disease. On LGE imaging, inferolateral mesocardial distributed LGE is a well-established feature of Fabry disease [56].

A key feature in the differential diagnosis of Fabry disease is intracellular lipid accumulation with fat vacuoles [56]. Fat has a very short T1 value (usually 250 ms), and fat vacuoles shorten the T1 value of the myocardium. Therefore, T1 mapping is useful for diagnosing Fabry disease. Various heart diseases, including HHD, HCM, cardiac amyloidosis, sarcoidosis, and AS, exhibit increased values on T1 mapping. Low native T1 values in the septum are strongly suggestive of Fabry disease rather than HCM or other cardiac diseases with LVH [57,58]. Furthermore, T1 values of the interventricular septum can be used to evaluate cardiac involvement in Fabry disease without LVH and to monitor treatment responses [59-61]. The ECV fraction and T2 values may increase in the area of hyperenhancement on LGE imaging, suggesting myocardial fibrosis or inflammatory changes [59,62]. However, myocardium with a low native T1 value typically demonstrates normal ECV fraction and T2 values (Fig. 5).

**Cardiac Amyloidosis**

Amyloidosis comprises a group of diseases underscored by the extracellular deposition of amyloid fibrils, which are insoluble proteins formed by the breakdown of normal and/or abnormal proteins [63,64]. Cardiac amyloidosis is uncommon; however, cardiac involvement in amyloidosis results in progressive restrictive cardiomyopathy and is a major prognostic factor in patients with systemic amyloidosis [65,66]. Two main types of cardiac amyloidosis exist, immunoglobulin light-chain amyloidosis (AL) and transthyretin amyloidosis (ATTR). ATTR is divided into mutant (ATTRm) and wild-type (ATTRwt) forms according to the presence or absence of genetic mutations [67]. Early diagnosis of cardiac amyloidosis is essential for a better prognosis [68]. CMR imaging has been employed for diagnosing cardiac amyloidosis with excellent sensitivity and specificity [64]. On cine images, asymmetric or symmetric LV wall thickening is common [69,70] and can be accompanied by thickening of the RV or atrial wall [71]. Strain analysis using cine images could help in the early diagnosis, severity evaluation, and prognosis assessment of cardiac amyloidosis [65]. Decreased strain parameters with relative apical sparing are well-known characteristics of cardiac amyloidosis [72]. However, strain abnormalities are not specific for cardiac amyloidosis [65]. Diffuse annular LGE is a typical finding in amyloidosis. However, various types of abnormal LGE are possible, including focal patchy, diffuse patchy, subendocardial, subepicardial, and diffuse transmural or global LGE [65]. Therefore, the differential diagnosis of HHD, HCM, and other restrictive cardiomyopathies can be challenging.

The key histological feature of cardiac amyloidosis is the deposition of amyloid fibrils in the myocardial interstitium and edematous changes [65]. On quantitative mapping...
images, cardiac amyloidosis presents as high T1 values, high T2 values, and a high ECV fraction, representing myocardial edematous changes (T1 and T2 values) or amyloid burden (T1 values and ECV fraction) [65,73]. In particular, ECV is substantially higher in patients with amyloidosis than in those with other conditions that cause LVH (Fig. 6) [58]. Compared to amyloidosis, ATTR tends to exhibit more extensive and transmural LGE, a higher ECV fraction, and lower T1 or T2 values, representing greater amyloid burden infiltration and less myocardial edema [64].

In addition, bone scintigraphy is useful for differentiating ATTR from AL. Bone scintigraphy using technetium 99m ($^{99m}$Tc) pyrophosphate, $^{99m}$Tc-3,3-diphosphono-1,2-propanodicarboxylic acid, and $^{99m}$Tc-hydroxymethylene diphosphonate revealed myocardial uptake of radiotracers with high sensitivity and specificity in patients with ATTR.
In contrast, patients with amyloidosis show no significant myocardial uptake [65].

**Mitochondrial Cardiomyopathy**

Mitochondrial myopathies are a heterogeneous group of disorders caused by mutations in the maternally inherited mitochondrial genome [76]. Mitochondrial myopathies are associated with dysfunctional energy production and multisystemic involvement of the central nervous system, heart, and skeletal system. Mitochondrial myopathy-related cardiac abnormalities include dilated cardiomyopathy and HCM phenotypes. The HCM phenotype is the most common cardiac abnormality in patients with mitochondrial disease-related cardiomyopathy [77] and is typically characterized by concentric LVH [76]. When mitochondrial cardiomyopathy...
presents as LVH, the differential diagnosis can be challenging [78], and the major role of cardiac imaging is to exclude other possible infiltrative or inflammatory diseases [79]. LGE images of patients with mitochondrial cardiomyopathies may exhibit non-coronary multifocal LGEs [79]. Perfusion MRI may indicate perfusion defects in LGEs [80] or subendocardial perfusion defects [79].

A key histological feature of mitochondrial cardiomyopathy is cardiomyocyte hypertrophy with vacuolar changes, derived from abnormal mitochondrial accumulation, which appears as a red fiber on modified Gomori trichrome staining. An increased number of swollen mitochondria with variable sizes and shapes constitutes a distinct feature in electron microscopic evaluation [79]. Intracellular vacuolar changes indicate increased water content in the myocardium, resulting in a diffuse increase in the T2 signal or values in the LV myocardium (Fig. 7). In addition, concomitant hearing loss, low skeletal mass, and pericardial effusion are suggestive of mitochondrial cardiomyopathy [79].

Fig. 7. CMR findings of mitochondrial cardiomyopathy based on histologic features.
A. A schematic illustration of the histological features of mitochondrial cardiomyopathy indicating myocyte hypertrophy with vacuolar changes.
B. On short-axis cine image of the end-diastolic phase, the LV shows concentric wall thickening. C. LGE imaging reveals the absence of focal abnormal hyperenhancement in the LV. D-F. The T2 maps (D, E) and bull’s eye diagram (F) show diffusely increased T2 values of the myocardium, measuring up to 69.8 ms on 1.5T MRI. G. The native T1 map shows diffusely increased native T1 values of the myocardium, measuring up to 1150 ms on 1.5T MRI. H. After contrast media injection, the myocardium reveals homogeneous post-T1 values in the LV. I. The ECV fraction map shows normal LV ECV fraction. CMR = cardiac magnetic resonance, ECV = extracellular volume, LGE = late gadolinium enhancement, LV = left ventricular
Sarcoidosis

Sarcoidosis is a multisystem disorder of unknown etiology. The histologic hallmark of sarcoidosis is the presence of non-caseating non-necrotic granulomas in the involved organs. The clinical manifestation of cardiac involvement occurs in approximately 5% of patients with sarcoidosis [81]. However, autopsy studies have estimated that the prevalence of cardiac involvement in patients with sarcoidosis is at least 25% [82]. The major clinical manifestations of cardiac sarcoidosis include conduction abnormalities, ventricular arrhythmias, and heart failure [83]. Patients with cardiac involvement have a poorer prognosis than those without cardiac involvement [84]. Thus, timely and accurate diagnosis and management of cardiac sarcoidosis is critical.

Fig. 8. CMR findings of cardiac sarcoidosis based on histologic features.

A. A schematic illustration of the histological features of sarcoidosis represents interstitial non-caseating granulomas, comprising a collection of epithelioid histiocytes and lymphocytes with multinucleated giant cells distributed along the lymphatics. B, C. On the short-axis cine image of the end-diastolic phase, basal thinning of the interventricular septum is noted (B), with epicardial or transmural enhancement on the LGE image (C). D, E. At the mid-left ventricular level, the interventricular septum shows mild thickening, measuring up to 16 mm (D), with hyperenhancement of the epicardial layer on the LGE image (E). F. The T2 map shows heterogeneously increased myocardial T2 values. G. The native T1 map shows increased native T1 values, measuring up to 1350 ms on 3T MRI. H. The post-T1 map demonstrates relatively lower post-T1 values at the epicardial layer of inferoseptal wall, corresponding to the LGE area. I. The LGE image of the basal level with fusion of 18F-labeled fluoro-2-deoxyglucose PET suggests active inflammation surrounding the regions of an established scar. CMR = cardiac magnetic resonance, LGE = late gadolinium enhancement.
A consensus statement on cardiac sarcoidosis by a consortium of international experts proposed LGE on CMR imaging as a criterion for the diagnosis of cardiac sarcoidosis [85]. The LGE pattern of cardiac sarcoidosis is patchy and multifocal with transmural involvement or sparing of the endocardial border; however, this pattern is nonspecific and overlaps substantially with that of other inflammatory and infiltrative cardiac diseases [86]. Furthermore, data on CMR strain in cardiac sarcoidosis are limited. Previously, Dabir et al. [87] reported that GLS was reduced in patients with cardiac sarcoidosis and associated with a negative outcome.

The histologic features of cardiac sarcoidosis differ according to the disease phase. The acute inflammatory phase is characterized by granulomatous infiltration, myocardial inflammation, and edema. This results in myocardial thickening, patchy increased signal intensity on T2-weighted images, and increased T2 values [88]. Native T1 values and ECV fractions are also elevated owing to acute myocardial inflammation or edema [89]. In the chronic phase, granulomatous infiltration results in replacement scarring and wall thinning, with regional wall motion abnormalities. Native T1 values and ECV fraction can be increased due to myocardial fibrosis, and scarring [89]. Recent studies have demonstrated that native T1 and T2 values enable non-invasive recognition of cardiac involvement and activity evaluation of sarcoidosis [90]. In addition, 18F-fluorodeoxyglucose PET, which is sensitive to metabolically active inflammation, has been widely reported to play a substantial role in the diagnosis and prognosis of cardiac sarcoidosis (Fig. 8) [91].

Table 1. Cardiac MRI Characteristics for Differentiation of Thickened Myocardium Based on Histologic Features

| Hypertrophic Cardiomyopathy | Hypertensive Heart Disease | Aortic Stenosis | Anderson-Fabry Disease | Amyloidosis | Mitochondrial Cardiomyopathy | Sarcoidosis | Athlete’s Heart |
|----------------------------|---------------------------|----------------|------------------------|------------|-----------------------------|-------------|----------------|
| LVH pattern                | Asymmetric > Concentric   | Concentric > Asymmetric | Concentric > Asymmetric | Concentric, Asymmetric | Concentric > Asymmetric | Concentric > Asymmetric | Concentric > Asymmetric |
| Unique histologic features | Cardiomyocyte hypertrophy, hypertrophic nuclei, disorganized myofibrillar arrangement, interstitial fibrosis | Cardiomyocyte hypertrophy with parallel alignment, interstitial and perivascular fibrosis | Cardiomyocyte hypertrophy and interstitial fibrosis | Mild cardiomyocyte hypertrophy, perinuclear and cytoplasmic vacuoles (lysosomal glycosphingolipid accumulation) | Extracellular homogenous, eosinophilic substance deposited in interstitium | Peripheral and intermyofibrillar accumulation of abnormal mitochondria: ragged red fiber on modified Gomori trichrome stain | Noncaseating epithelioid granulomas and multinucleated giant cells in interstitium, distributed along the lymphatics |
| T1 value                   | ↑                         | ↑             | ↑                      | ↑↑         | ↑                          | ↑           | ↑ (acute)       |
| T2 value                   | ↑             | ↔             | ↔                      | ↑↑         | ↑                          | ↑           | ↔              |
| ECV fraction               | ↑             | ↑             | ↑                      | ↑↑         | ↔                         | ↔           | ↑              |
| LGE                        | ++/+/-                  | +/-           | +/-                    | ++/+       | +/-                        | ++/+        | Rare           |
| Multifocal patch           | Inferolateral            | Circular subendocardial | Multifocal patch, epicardial | Loss of base-to-apex circumferential strain gradient | Relative apical sparing | Proportional cavity enlargement, improved LVH after detraining |
| LV strain on CMR           | ↓                         | ↓             | ↓                      | ↓          | ↓                          | ↓           | ↔              |
| Additional features        | LVOT jet flow, small LV cavity | Hypertension | AV jet flow | Systemic involvement | Atrial involvement, pericardial or pleural effusion | Hearing loss, low skeletal mass, and pericardial effusion | FDG PET (+) |

AS = aortic valve stenosis, AV = aortic valve, CMR = cardiac magnetic resonance, ECV = extracellular volume, FDG = fluorodeoxyglucose, LGE = late gadolinium enhancement, LV = left ventricular, LVH = left ventricular hypertrophy, LVOT = left ventricular outflow tract, ↑ = mild increase, ↑↑ = moderate to marked increase, ↓ = mild decrease, ↓↓ = moderate to marked decrease, ↔ = within normal range.
Athlete's Heart

Athlete’s heart occurs because of cardiac adaptations to high-intensity exercise and is characterized by increased LV volume, increased LV wall thickness, increased myocardial mass, resting bradycardia, and electrocardiogram abnormalities [32,92]. SCD is fairly common in young athletes, and HCM is the most common cause of SCD among athletes. Therefore, differential diagnosis of athlete’s heart from HCM is crucial but can be challenging [93].

Athlete’s heart is underpinned by physiological remodeling, whereas HCM is underscored by pathological remodeling [94]. LV EDWT in athlete’s heart is typically < 15 mm, and only 1.5% of athletes exhibit LV wall thickness > 15 mm [95,96]. LV wall thickening in athlete’s heart is diffuse, and the chamber enlargement is proportional, as this condition is a result of physiologic wall stress and pressure [32]. In HCM, the LV end-diastolic cavity size is generally decreased and the LV end-diastolic diameter (LVEDD) is < 45 mm. In contrast, in athlete’s heart, the LV cavity is enlarged and the LVEDD is > 55 mm. HCM presents as diastolic dysfunction and hyperdynamic LV systolic function, whereas diastolic dysfunction is not observed in athlete’s heart [32]. Although various features can be used to differentiate athlete’s heart from HCM, considerable ambiguity exists [93,97]. A recent study by Giusca et al. [98] showed that CMR-derived myocardial strain could aid in the differentiation between athlete’s heart and HCM, and between athlete’s heart and HHD. In contrast to HCM and HHD, the GLS of patients with athlete’s heart did not differ significantly from that of the healthy participants.

Histologically, athlete’s heart is characterized by increased LV mass, expansion of the cellular compartment, and smaller ECV [94], which are distinct features on CMR imaging. Abnormal focal LGE is rare in untrained individuals and athletes. Native T1 values and ECV fractions were significantly lower in athletes than in untrained individuals [99]. High-performance athletes exhibited a very low ECV fraction and increased intracellular mass index. Furthermore, a higher LV mass is correlated with a lower ECV fraction [99,100]. An increase in LV mass is associated with a reduction in ECV in athletes, but an increase in ECV in patients with HCM [100]. Thus, the absence of typical HCM features, lack of LGE, low native T1 values, and a low ECV fraction may be crucial findings in CMR imaging for differentiating athlete’s heart from HCM typically showing multifocal patchy LGE, increased native T1 and T2 values, and an increased ECV fraction.

CONCLUSIONS

An accurate differential diagnosis of LVH is mandatory to ensure appropriate treatment. The greatest strength of CMR imaging is its ability to provide various tissue contrasts and characteristics that reflect the histological changes in the myocardium. With technical innovations, CMR imaging may provide multiparametric information, including T1 and T2 values, ECV fraction, and strain data (Table 1). Although the differential diagnosis of LVH can be complex, CMR imaging enables reasonable interpretations of myocardial conditions using multiparametric analysis. This will enable the exclusion of inappropriate diagnoses and narrowing down of other potential diseases. A more precise CMR analysis based on a deeper understanding of the pathophysiological mechanisms will improve the accuracy of the differential diagnosis of LVH.

Availability of Data and Material

Data sharing does not apply to this article as no datasets were generated or analyzed during the current study.

Conflicts of Interest

Tae Hoon Kim who is on the editorial board of the Korean Journal of Radiology was not involved in the editorial evaluation or decision to publish this article. All remaining authors have declared no conflicts of interest.

Author Contributions

Conceptualization: Min Jae Cha, Yoon Jin Cha, Chul Hwan Park. Investigation: Cherry Kim, Chan Ho Park, Yoo Jin Hong, Jae Min Shin. Methodology: Min Jae Cha, Cherry Kim, Yoon Jin Cha, Chul Hwan Park. Project administration: Yoon Jin Cha, Chul Hwan Park. Supervision: Yoo Jin Hong, Tae Hoon Kim. Validation: Min Jae Cha, Yoon Jin Cha, Chul Hwan Park. Writing—original draft: all authors. Writing—review & editing: Min Jae Cha, Yoon Jin Cha, Yoo Jin Hong, Chul Hwan Park.

ORCID iDs

Min Jae Cha
https://orcid.org/0000-0001-6358-8081
Cherry Kim
https://orcid.org/0000-0002-3361-5496
Chan Ho Park
https://orcid.org/0000-0002-0653-4666
The authors wish to thank Ms. Inseon Park for all artistic support related to this work.

REFERENCES

1. Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 1988;108:7-13
2. Hansen MW, Merchant N. MRI of hypertrophic cardiomyopathy: part I, MRI appearances. AJR Am J Roentgenol 2007;189:1335-1343
3. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary artery risk development in (young) adults. Circulation 1995;92:785-789
4. Méndez C, Soler R, Rodríguez E, Barriales R, Ochoa JP, Monserrat L. Differential diagnosis of thickenened myocardium: an illustrative MRI review. Insights Imaging 2018;9:695-707
5. Hansen MW, Merchant N. MRI of hypertrophic cardiomyopathy: part 2, differential diagnosis, risk stratification, and posttreatment MRI appearances. AJR Am J Roentgenol 2007;189:1344-1352
6. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 2000;102:470-479
7. Giesbrantd KJ, Bolan CW, Shapiro BP, Edwards WD, Mergo PJ. Diffuse diseases of the myocardium: MRI-pathologic review of nondilated cardiomyopathies. AJR Am J Roentgenol 2013;200:W266-W273
8. Varma PK, Neema PK. Hypertrophic cardiomyopathy: part 1 - introduction, pathology and pathophysiology. Ann Card Anaesth 2014;17:118-124
9. Saremi F, Sánchez-Quintana D, Mori S, Muresian H, Spicer DE, Hassani C, et al. Fibrous skeleton of the heart: anatomic overview and evaluation of pathologic conditions with CT and MR imaging. Radiographics 2017;37:1330-1351
10. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002;287:1308-1320
11. O’Hanlon R, Pennell DJ. Cardiovascular magnetic resonance in the evaluation of hypertrophic and infiltrative cardiomyopathies. Heart Fail Clin 2009;5:369-387, vi
12. Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol 2015;65:1249-1254
13. Klues HG, Schieffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol 1995;26:1699-1708
14. Noureldin RA, Liu S, Nacif MS, Judge DP, Halushka MK, Abraham TP, et al. The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2012;14:17
15. O’Hanlon R, Assomull RG, Prasad SK. Use of cardiovascular magnetic resonance for diagnosis and management in hypertrophic cardiomyopathy. Curr Cardiol Rep 2007;9:51-56
16. Baxi AJ, Restrepo CS, Vargas D, Marmol-Velez A, Ocazionez D, Murillo H. Hypertrophic cardiomyopathy from A to Z: genetics, pathophysiology, imaging, and management. Radiographics 2016;36:335-354
17. Elliott PM, Anastasakis A, Borger MA, Borggreve M, Cecchi F, Charron P, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014;35:2733-2779
18. Burrage MK, Ferreira VM. Cardiovascular magnetic resonance for the differentiation of left ventricular hypertrophy. Curr Heart Fail Rep 2020;17:192-204
19. Quarta G, Aquaro GD, Pedrotti P, Pontone G, Dellefrottaglie S, Iacovoni A, et al. Cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy: the importance of clinical context. Eur Heart J Cardiovasc Imaging 2018;19:601-610
20. Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2010;56:875-887
21. Mentias A, Raesi-Giglou P, Smedira NG, Feng K, Sato K, Wazni O, et al. Late gadolinium enhancement in patients with hypertrophic cardiomyopathy and preserved systolic function. J Am Coll Cardiol 2018;72:857-870
22. Mewton N, Liu CY, Croisille P, Bluekme D, Lima JA. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol 2011;57:891-903
23. Hinojar R, Varma N, Child N, Goodman B, Jabbour A, Yu CY, et al. T1 mapping in discrimination of hypertrophic
Differential Diagnosis of Thick Myocardium Using Cardiac MRI

phenotypes: hypertensive heart disease and hypertrophic cardiomyopathy: findings from the international T1 multicenter cardiovascular magnetic resonance study. Circ Cardiovasc Imaging 2015;8:e003285
24. Axelsson Raja A, Farhad H, Valente AM, Couce JP, Jefferies JL, Bundgaard H, et al. Prevalence and progression of late gadolinium enhancement in children and adolescents with hypertrophic cardiomyopathy. Circulation 2018;138:782-792
25. Xu J, Zhuang B, Sirajuddin A, Li S, Huang J, Yin G, et al. MRI T1 mapping in hypertrophic cardiomyopathy: evaluation in patients without late gadolinium enhancement and hemodynamic obstruction. Radiology 2020;294:275-286
26. Huang L, Lan L, Zhao P, Tang D, Han R, Ai T, et al. MRI native T1 and T2 mapping of myocardial segments in hypertrophic cardiomyopathy: tissue remodeling manifested prior to structure changes. Br J Radiol 2019;92:20190634
27. Gommans DHF, Cramer GE, Bakker J, Dieker HJ, Michels M, Fournax MA, et al. High T2-weighted signal intensity for risk prediction of sudden cardiac death in hypertrophic cardiomyopathy. Int J Cardiovasc Imaging 2018;34:113-120
28. Neisius U, Myerson L, Fahmy AS, Nakamori S, El-Rewaide H, Joshi G, et al. Cardiac magnetic resonance feature tracking strain analysis for discrimination between hypertensive heart disease and hypertrophic cardiomyopathy. PLoS One 2019;14:e0221061
29. Rodrigues JC, Rohan S, Ghosh Dastidar A, Harries I, Lawton CB, Ratcliffe LE, et al. Hypertensive heart disease versus hypertrophic cardiomyopathy: multi-parametric cardiovascular magnetic resonance discriminators when end-diastolic wall thickness ≥ 15 mm. Eur Radiol 2017;27:1125-1135
30. Sipola P, Magga J, Hussein M, Jääskeläinen P, Peuhkurinen K, Kuusisto J. Cardiac MRI assessed left ventricular hypertrophy in differentiating hypertensive heart disease from hypertrophic cardiomyopathy attributable to a sarcomeric gene mutation. Eur Radiol 2011;21:1383-1389
31. Maceira AM, Mohiaddin RH. Cardiovascular magnetic resonance in systemic hypertension. J Cardiovasc Magn Reson 2012;14:28
32. Carbone A, D’Andrea A, Riegler L, Scarafile R, Pezzullo E, Martone F, et al. Cardiac damage in athlete’s heart: when the “supernormal” heart fails! World J Cardiol 2017;9:470-480
33. Rudolph A, Abdel-Aty H, Bohl S, Boyé P, Zagrosek A, Dietz R, et al. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. J Am Coll Cardiol 2009;53:284-291
34. Puntmann VO, Jahike C, Gebker R, Schnackenburg B, Fox KF, Fleck E, et al. Usefulness of magnetic resonance imaging to distinguish hypertensive and hypertrophic cardiomyopathy. Am J Cardiol 2010;106:1016-1022
35. Wu LM, Wu R, Ou YR, Chen BH, Yao QY, Lu Q, et al. Fibrosis quantification in hypertensive heart disease with LVH and non-LVH: findings from T1 mapping and contrast-free cardiac diffusion-weighted imaging. Sci Rep 2017;7:559
36. Kato TS, Noda A, Izawa H, Yamada O, Obata K, Nagata K, et al. Discrimination of nonobstructive hypertrophic cardiomyopathy from hypertensive left ventricular hypertrophy on the basis of strain rate imaging by tissue Doppler ultrasonography. Circulation 2004;110:3808-3814
37. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet 2006;368:1005-1011
38. Hein S, Arnon E, Kostin S, Schönburg M, Elssasser A, Polyakova V, et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 2003;107:984-991
39. Dweck MR, Joshi S, Murigú T, Gulati A, Alpendurada F, Jabbour A, et al. Left ventricular remodeling and hypertrophy in patients with aortic stenosis: insights from cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2012;14:50
40. Grossman W. Cardiac hypertrophy: useful adaptation or pathologic process? Am J Med 1980;69:576-584
41. Debry N, Maréchaux S, Rusiniu D, Peltier M, Messika-Zeitoun D, Menet A, et al. Prognostic significance of left ventricular concentric remodelling in patients with aortic stenosis. Arch Cardiovasc Dis 2017;110:26-34
42. Dweck MR, Joshi S, Murigú T, Alpendurada F, Jabbour A, et al. Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. J Am Coll Cardiol 2011;58:1271-1279
43. Kräymerbuehl HP, Hess OM, Monrad ES, Schneider J, Mall G, Turina M. Left ventricular myocardial structure in aortic valve disease before, intermediate, and late after aortic valve replacement. Circulation 1989;79:744-755
44. Singh A, Horsfield MA, Bekele S, Khan JN, Greiser A, McCann GP. Myocardial T1 and extracellular volume fraction measurement in asymptomatic patients with aortic stenosis: reproducibility and comparison with age-matched controls. Eur Heart J Cardiovasc Imaging 2015;16:763-770
45. Treibel TA, Kozor R, Schofield R, Benedetti G, Fontana M, Bhuvu AN, et al. Reverse myocardial remodeling following valve replacement in patients with aortic stenosis. J Am Coll Cardiol 2018;71:860-871
46. Everett RJ, Treibel TA, Fukui M, Lee H, Rigolli M, Singh A, et al. Extracellular myocardial volume in patients with aortic stenosis. J Am Coll Cardiol 2020;75:304-316
47. Park SJ, Cho SW, Kim SM, Ahn J, Carriere K, Jeong DS, et al. Assessment of myocardial fibrosis using multimodality imaging in severe aortic stenosis: comparison with histologic fibrosis. JACC Cardiovasc Imaging 2019;12:109-119
48. Hwang JW, Kim SM, Park SJ, Cho EJ, Kim EK, Chang SA, et al. Assessment of reverse remodeling predicted by myocardial deformation on tissue tracking in patients with
severe aortic stenosis: a cardiovascular magnetic resonance imaging study. J Cardiovasc Magn Reson 2017;19:80

49. Musa TA, Uddin A, Swoboda PP, Fairbairn TA, Dobson LE, Singh A, et al. Cardiovascular magnetic resonance evaluation of symptomatic severe aortic stenosis: association of circumferential myocardial strain and mortality. J Cardiovasc Magn Reson 2017;19:13

50. Kim MY, Park EA, Lee W, Lee SP. Cardiac magnetic resonance feature tracking in aortic stenosis: exploration of strain parameters and prognostic value in asymptomatic patients with preserved ejection fraction. Korean J Radiol 2020;21:268-279

51. Yogasundaram H, Kim D, Oudit O, Thompson RB, Weidemann F, Oudit GY. Clinical features, diagnosis, and management of patients with Anderson-Fabry cardiomyopathy. Can J Cardiovasc Pathol 2017;33:883-897

52. El-Abassi R, Singhal D, England JD. Fabry's disease. J Neurol Sci 2014;344:5-19

53. Zarate YA, Hopkin RJ. Fabry's disease. Lancet 2008;372:1427-1435

54. Wu JC, Ho CY, Skali H, Abichandani R, Wilcox WR, Banikazemi M, et al. Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity. Eur Heart J 2010;31:1088-1097

55. Mathur S, Dreibusch JG, Karur GR, Iwanochko RM, Morel CF, Wasim S, et al. Loss of base-to-apex circumferential strain gradient assessed by cardiovascular magnetic resonance in Fabry disease: relationship to T1 mapping, late gadolinium enhancement and hypertrophy. J Cardiovasc Magn Reson 2019;21:45

56. Moon JC, Sachdev B, Elkington AG, McKenna WJ, Mehta A, Pennell DJ, et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 2003;24:2151-2155

57. Karur GR, Robison S, Iwanochko RM, Morel CF, Crean AM, Thavendiranathan P, et al. Use of myocardial T1 mapping at 3.0 T to differentiate Anderson-Fabry disease from hypertrophic cardiomyopathy. Radiology 2018;288:398-406

58. Pica S, Sado DM, Maestrini V, Fontana M, White SK, Treibel T, et al. Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2014;16:99

59. Sado DM, White SK, Piechnik SK, Banyersad SM, Treibel T, Captur G, et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging 2013;6:392-398

60. Camporeale A, Pieroni M, Pieruzzi F, Lusardi P, Pica S, Spada M, et al. Predictors of clinical evolution in prehypertrophic Fabry disease. Circ Cardiovasc Imaging 2019;12:e008424

61. Weidemann F, Niemann M, Störk S, Breunig F, Beer M, Sommer C, et al. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med 2013;274:331-341

62. Nordin S, Kozor R, Medina-Menacho K, Abdel-Gadir A, Baig S, Sado DM, et al. Proposed stages of myocardial phenotype development in Fabry disease. JACC Cardiovasc Imaging 2019;12:1673-1683

63. Banyersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in cardiac amyloidosis: a review. J Am Heart Assoc 2012;1:e000364

64. Fontana M, Banyersad SM, Treibel TA, Abdel-Gadir A, Maestrini V, Lane T, et al. Differential myocyte responses in patients with cardiac transthyretin amyloidosis and light-chain amyloidosis: a cardiac MR imaging study. Radiology 2015;277:388-397

65. Oda S, Kidoh M, Nagayama Y, Takashio S, Usuku H, Ueda M, et al. Trends in diagnostic imaging of cardiac amyloidosis: emerging knowledge and concepts. Radiographics 2020;40:961-981

66. Izumiya Y, Takashio S, Oda S, Yamashita Y, Tsujita K. Recent advances in diagnosis and treatment of cardiac amyloidosis. J Cardioiol 2018;71:135-143

67. Maleszewska JJ. Cardiac amyloidosis: pathology, nomenclature, and typing. Cardiovasc Pathol 2015;24:343-350

68. Philippakis AA, Falk RH. Cardiac amyloidosis mimicking hypertrophic cardiomyopathy with obstruction: treatment with disopyramide. Circulation 2012;125:1821-1824

69. Pozo E, Kanwar A, Deochand R, Castellano JM, Naib T, Pazos-López P, et al. Cardiac magnetic resonance evaluation of left ventricular remodelling distribution in cardiac amyloidosis. Heart 2014;100:1688-1695

70. Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS, et al. Magnetic resonance in transthyretin cardiac amyloidosis. J Am Coll Cardiol 2017;70:466-477

71. Fattori R, Rocchi G, Celletti F, Bertaccini P, Rabezzi C, Gavelli G. Contribution of magnetic resonance imaging in the differential diagnosis of cardiac amyloidosis and symmetric hypertrophic cardiomyopathy. Am Heart J 1998;136:824-830

72. Kim JY, Hong YJ, Han K, Lee HJ, Hur J, Kim YJ, et al. Regional amyloid burden differences evaluated using quantitative cardiac MRI in patients with cardiac amyloidosis. Korean J Radiol 2021;22:880-889

73. Haaf P, Garg P, Messroghli DR, Broadbent DA, Greenwood JP, Plein S. Cardiac T1 mapping and extracellular volume (ECV) in clinical practice: a comprehensive review. J Cardiovasc Magn Reson 2016;18:99

74. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404-2412

75. Ruberg FL, Miller EJ. Nuclear tracers for transthyretin cardiac amyloidosis: time to bone up? Circ Cardiovasc Imaging
Differential Diagnosis of Thick Myocardium Using Cardiac MRI

2013;6:162-164
76. Florian A, Ludwig A, Stubbe-Dräger B, Boentert M, Young P, Waltenberger J, et al. Characteristic cardiac phenotypes are detected by cardiovascular magnetic resonance in patients with different clinical phenotypes and genotypes of mitochondrial cardiomyopathy. J Cardiovasc Magn Reson 2015;17:40
77. Dimmock DP, Lawlor MW. Presentation and diagnostic evaluation of mitochondrial disease. Pediatr Clin North Am 2017;64:161-171
78. Kuno T, Imaeda S, Asakawa Y, Nakamura H, Takemura G, Asahara D, et al. Mitochondrial cardiomyopathy presenting as dilated phase of hypertrophic cardiomyopathy diagnosed with histological and genetic analyses. Case Rep Cardiol 2017;2017:9473917
79. Partington SL, Givertz MM, Gupta S, Kwong RY. Cardiac magnetic resonance aids in the diagnosis of mitochondrial cardiomyopathy. Circulation 2011;123:e227-e229
80. Nakashishi M, Harada M, Tadamura E, Kotani H, Kawakami R, Kuwahara K, et al. Images in cardiovascular medicine. Mitochondrial cardiomyopathy evaluated with cardiac magnetic resonance. Circulation 2007;116:e25-e26
81. Dubrey SW, Falk RH. Diagnosis and management of cardiac sarcoidosis. Prog Cardiovasc Dis 2010;52:336-346
82. Iwai K, Tachibana T, Takemura T, Matsui Y, Kitaichi M, Kawabata Y. Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan. Acta Pathol Jpn 1993;43:372-376
83. Birnie DH, Nery PB, Ha AC, Beanlands RS. Cardiac sarcoidosis. J Am Coll Cardiol 2016;68:411-421
84. Sadek MM, Yung D, Birnie DH, Beanlands RS, Nery PB. Corticosteroid therapy for cardiac sarcoidosis: a systematic review. Can J Cardiol 2013;29:1034-1041
85. Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvennoy CS, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11:1305-1323
86. Jeeby J, Burke AP, White CS, Kramer GB, Frazier AA. Cardiac sarcoidosis: the challenge of radiologic-pathologic correlation: from the radiologic pathology archives. Radiographics 2015;35:657-679
87. Dabir D, Meyer D, Kuetting D, Luetkens J, Homsi P, Rizzaro C, et al. Diagnostic value of cardiac magnetic resonance strain analysis for detection of cardiac sarcoidosis. Rofo 2018;190:712-721
88. Vignaux O, Dhothe R, Duboc D, Blanche P, Devaux JY, Weber S, et al. Detection of myocardial involvement in patients with sarcoidosis applying T2-weighted, contrast-enhanced, and cine magnetic resonance imaging: initial results of a prospective study. J Comput Assist Tomogr 2002;26:762-767
89. Greulich S, Kitterer D, Latus J, Aguer E, Steubing H, Kaesemann P, et al. Comprehensive cardiovascular magnetic resonance assessment in patients with sarcoidosis and preserved left ventricular ejection fraction. Circ Cardiovasc Imaging 2016;9:e005022
90. Puntmann VO, Isted A, Hinojar R, Foote L, Carr-White G, Nagel E. T1 and T2 mapping in recognition of early cardiac involvement in systemic sarciodsis. Radiology 2017;285:63-72
91. Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012;53:241-248
92. Plumim BM, Zwinderman AH, van der Laarse A, van der Wall EE. The athlete's heart. A meta-analysis of cardiac structure and function. Circulation 2000;101:336-344
93. Maron BJ, Pelliccia A. The heart of trained athletes: cardiac remodeling and the risks of sports, including sudden death. Circulation 2006;114:1633-1644
94. Bernardo BC, Weeks KL, Pretorius L, McMullen JR. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther 2010;128:191-227
95. Basavarajaiah S, Wilson M, Whyte G, Shah A, McKenna W, Sharma S. Prevalence of hypertrophic cardiomyopathy in highly trained athletes: relevance to pre-participation screening. J Am Coll Cardiol 2008;51:1033-1039
96. Scharhag J, Schneider G, Urhausen A, Rochette V, Kramann B, Kindermann W. Athlete's heart: right and left ventricular mass and function in male endurance athletes and untrained individuals determined by magnetic resonance imaging. J Am Coll Cardiol 2002;40:1856-1863
97. Lauschke J, Maisch B. Athlete's heart. A meta-analysis of cardiac structure and function. Circulation 2000;101:336-344
98. Barlow BJ, Lyall GK, Broadbent DA, et al. Athletic cardiac adaptation volume by T1 mapping to distinguish hypertrophic cardiomyopathy from athlete's heart. J Cardiovasc Magn Reson 2016;23:92 597
99. McDaid AK, McDiarmid AK, Swoboda PP, Erhayiem B, Lancaster RE, Giusca S, Steen H, Montenbruck M, Patel AR, Pieske B, Erley J, et al. Mitochondrial cardiomyopathy evaluated with cardiac magnetic resonance. 2011;123:e227-e229
100. Swoboda PP, McDiarmid AK, Erhayiem B, Broadbent DA, Puntmann VO, Isted A, Hinojar R, Foote L, Carr-White G, Nagel E. T1 and T2 mapping in recognition of early cardiac involvement in systemic sarciodsis. Radiology 2017;285:63-72
101. Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012;53:241-248
102. Plumim BM, Zwinderman AH, van der Laarse A, van der Wall EE. The athlete's heart. A meta-analysis of cardiac structure and function. Circulation 2000;101:336-344
103. Maron BJ, Pelliccia A. The heart of trained athletes: cardiac remodeling and the risks of sports, including sudden death. Circulation 2006;114:1633-1644
104. Bernardo BC, Weeks KL, Pretorius L, McMullen JR. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther 2010;128:191-227
105. Basavarajaiah S, Wilson M, Whyte G, Shah A, McKenna W, Sharma S. Prevalence of hypertrophic cardiomyopathy in highly trained athletes: relevance to pre-participation screening. J Am Coll Cardiol 2008;51:1033-1039
106. Scharhag J, Schneider G, Urhausen A, Rochette V, Kramann B, Kindermann W. Athlete’s heart: right and left ventricular mass and function in male endurance athletes and untrained individuals determined by magnetic resonance imaging. J Am Coll Cardiol 2002;40:1856-1863
107. Lauschke J, Maisch B. Athlete’s heart or hypertrophic cardiomyopathy? Clin Res Cardiol 2009;98:80-88
108. Giusca S, Steen H, Montenbruck M, Patel AR, Lieske B, Erley J, et al. Multi-parametric assessment of left ventricular hypertrophy using late gadolinium enhancement, T1 mapping and strain-encoded cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2021;23:92
109. McDaid AK, Swoboda PP, Erhayiem B, Lancaster RE, Lyall GK, Broadbent DA, et al. Athletic cardiac adaptation mass and function in male endurance athletes and untrained individuals determined by magnetic resonance imaging. J Am Coll Cardiol 2002;40:1856-1863
110. Scharhag J, Schneider G, Urhausen A, Rochette V, Kramann B, Kindermann W. Athlete’s heart: right and left ventricular mass and function in male endurance athletes and untrained individuals determined by magnetic resonance imaging. J Am Coll Cardiol 2002;40:1856-1863
111. Lauschke J, Maisch B. Athlete’s heart or hypertrophic cardiomyopathy? Clin Res Cardiol 2009;98:80-88